841290-80-0 | 6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-2H-pyrido[3,2-b]

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$23.00	$16.00
2mg	95%	in stock	$29.00	$20.00
5mg	95%	in stock	$35.00	$24.00
10mg	95%	in stock	$42.00	$29.00
250mg	95%	in stock	$57.00	$40.00
1g	95%	in stock	$137.00	$96.00
5g	95%	in stock	$448.00	$314.00

Description

• Catalog Number: AD94983
• Chemical Name: 6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-2H-pyrido[3,2-b]
• CAS Number: 841290-80-0
• Molecular Formula: C22H23FN6O5
• Molecular Weight: 470.4536
• MDL Number: MFCD09970820
• SMILES: COc1cc(Nc2ncc(c(n2)Nc2ccc3c(n2)NC(=O)C(O3)(C)C)F)cc(c1OC)OC

Computed Properties

• Complexity: 691
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 34
• Hydrogen Bond Acceptor Count: 11
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 7
• XLogP3: 3.1

Literature

• Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.

  Journal of medicinal chemistry 20140508

• Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

  Journal of medicinal chemistry 20131024

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Rational design of highly selective spleen tyrosine kinase inhibitors.

  Journal of medicinal chemistry 20121213

• Discovery and development of spleen tyrosine kinase (SYK) inhibitors.

  Journal of medicinal chemistry 20120426

• Comprehensive analysis of kinase inhibitor selectivity.

  Nature biotechnology 20111030

• Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.

  Protein science : a publication of the Protein Society 20110201

• Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

  Chemistry & biology 20101124

• Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes.

  Chemical biology & drug design 20090401

• Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.

  Bioorganic & medicinal chemistry letters 20090401

• Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing.

  Birth defects research. Part A, Clinical and molecular teratology 20090201

• R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.

  The Journal of pharmacology and experimental therapeutics 20061201